R N Pearse
Affiliation: Cornell University
- Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progressionR N Pearse
Laboratories of Molecular Genetics and Immunology, and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10021, USA
Proc Natl Acad Sci U S A 98:11581-6. 2001..Our data identify TRANCE and OPG as key cytokines whose deregulation promotes bone destruction and supports myeloma growth...
- A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survivalRoger N Pearse
Division of Hematology, Cornell University Medical College, Rm C 606, 1300 York Ave, New York, NY 10021, USA
Blood 105:4429-36. 2005..Finally, BDNF is expressed by malignant plasma cells isolated from a subset of patients with MM, as well as by most HMCLs, suggesting a potential role for this neurotrophin axis in autocrine as well as paracrine support of MM...
- New strategies for the treatment of metastatic bone diseaseRoger N Pearse
Department of Medicine, Division of Hematology Medical Oncology, Cornell University, 1300 York Avenue, New York, NY 10065, USA
Clin Breast Cancer 8:S35-45. 2007....
- Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodelingRoger N Pearse
Division of Hematology Oncology, Cornell University Medical College, New York, New York 10021, USA
Clin Cancer Res 12:6274s-6278s. 2006..Inhibition of bone formation may result from the ability of MM to inhibit the function of Wnts, secreted glycoproteins critical to osteoblast development. Recent studies show how these processes may be linked...
- Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myelomaTomer Mark
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital Cornell Medical Center, New York, New York 10021, USA
Biol Blood Marrow Transplant 14:795-8. 2008..91). In conclusion, Cy can be added to G-CSF for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide...
- BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myelomaRuben Niesvizky
Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
Blood 111:1101-9. 2008..BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma. This trial was registered at www.clinicaltrials.gov as #NCT00151203...
- Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapyRuben Niesvizky
Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York Presbytarian Hospital Cornell Medical Center, New York, NY 10021, USA
Br J Haematol 138:640-3. 2007..Caution should be exercised when lenalidomide therapy is commenced and CrCl should be incorporated as a determinant of the initial dosing of lenalidomide in MM patients...
- Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myelomaTomer Mark
Department of Medicine, Division of Hematology and Medical Oncology, Center of Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
Br J Haematol 143:654-60. 2008..This is the first time this phenomenon has been seen with regularity in non-myeloablative therapy for MM. Analogous to the ASCT experience, ASIPs do not signal incipient disease progression, but rather herald robust response...
- Advances in treating metastatic bone cancer: summary statement for the First Cambridge ConferenceAllan Lipton
Milton S Hershey Medical Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033 0850, USA, and Department of Oncology, Norwegian Radium Hospital, Oslo, Norway
Clin Cancer Res 12:6209s-6212s. 2006..The conclusions reached during the 2-day meeting are summarized in this article and presented in more detail in the individual articles and accompanying discussion sessions that comprise the conference proceedings...
- Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activityShmuel Yaccoby
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 116:278-90. 2002..Breaking this loop may help control myeloma...